Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Sponsor
Alliance for Clinical Trials in Oncology
Status
Recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT04939090
This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss.
Intervention
Megestrol Acetate, Olanzapine, Questionnaire Administration
Condition
Advanced Malignant Solid Neoplasm, Anorexia, Hematopoietic and Lymphoid Cell Neoplasm
Investigators
Aminah Jatoi, MD, Bryan A. Faller, Kendrith M. Rowland, Deborah W. Wilbur, Grant R. Seeger, Isoken Koko, Erica D. Lovett Fournier, Gregory A. Masters, Adam W. Nowlan, Joseph J. Merchant, Bret E. Friday, Daniel M. Anderson, Mark A. Klein, Yeun-Hee A. Park, Kunal C. Kadakia, Samer S. Kasbari, Sorab Gupta, Namrata I. Peswani, Anthony J. Jaslowski, Michael O. Ojelabi, Site Public Contact, Steven E. Sckolnik, Matthias Weiss, Shahzad Siddique, Latha S. Neerukonda, Richard M. Schraeder, Jacob M. Elkon, Vijaya K. Gadiyaram, Leandro P. Moraes, Charles S. Kuzma, Donald J. Jurgens, Bolanle Gbadamosi, Mandana Kamgar, John A. Ellerton, John M. Schallenkamp, Ashley Springer, Melanie M. Smith, Steven Ades, Bridget N. Fahy, John H. Farley, Joyson Poulose, Anita Ravipati, Seema Harichand-Herdt, Ki Y. Chung, Pam G. Khosla, Tareq Al baghdadi, Sohail A. Minhas, William A. Wilson, Shafia Rahman, Nicholas J. DiBella, Douglas E. Laux, Daniel Almquist